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Goals:  
A Constructive Technology Assessment (CTA) has been performed on the 70-
gene signature, a genomic profile for breast cancer diagnostics. CTA is a new, 
prospective evaluation which can provide information for decision makers in an 
early stage of technology development. Besides cost-effectiveness it takes 
technology dynamics into account. To incorporate the dynamics, we used 
scenarios to forecast the implementation process of the 70-gene signature. As 
part of the scenarios, patient cases were used to investigate whether and how 
physicians are considering using a genomic profile and how they change their 
adjuvant treatment advice.  
Methods:  
We drafted 3 scenarios with different alternatives on the subsequent phases of 
diffusion (spreading of the 70-gene signature) throughout Europe; mid-2004, 
2005 and 2008, respectively before, during and after introduction. The scenarios 
were checked by expert opinions, set out by means of questionnaires and 
discussed in a workshop with 50 European breast cancer experts. Six patient 
cases were included in the questionnaire, differing in clinical prognostic factors 
and outcomes of the 70-gene signature and Oncotype DX.  
Results:  
Surprisingly, the first scenario regarding a discussion on validity of the 70-gene 
signature proved to be realistic; this resulted in a design for the MINDACT-trial, a 
randomized trial to test the clinical benefit of the 70-gene signature. The most 
markable (and likely to influence the cost-effectiveness) scenarios for the coming 
10 years were: Competition with the Oncotype DX (50% likely), coverage 
problems (25% likely), non-believers who could delay the diffusion (100% likely), 
increased use of fresh frozen tissue, which could increase the use of the 70-gene 
signature (85% likely). In 60% of the patient cases (n=22), physicians were 
considering to use a genomic profile. Addition of chemotherapy and/or endocrine 
therapy in high/intermediate genomic risks was more seen than leaving out 
adjuvant therapy in low risk cases. Detailed calculations will be presented during 
the conference. 
Conclusions:  
The confidence in the 70-gene signature is likely to progress in time and to be 
used as intended. Scenario drafting can be used as a tool in forecasting new, still 
dynamic technologies, in order to provide the decision maker information on the 
potential and likely cost-effectiveness in clinical practice. 
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